In this study, the relevant biomarkers for predicting the efficacy of neoadjuvant therapy in patients with MIBC were further explored. Meanwhile, the dynamic molecular monitoring of neoadjuvant therapy in MIBC patients and the treatment guidance based on the MHC tumor immune microenvironment were also explored to select the treatment plan based on relevant biomarkers for subsequent immunotherapy in MIBC patients.
Male or female, aged ≥18 years.
Expected survival ≥12 weeks.
Diagnosed by histopathology as muscle-invasive bladder urothelial carcinoma (MIBC) without upper urothelial carcinoma.
Clinical stage (cT2-T4a, N0-1, M0) and no distant metastasis as evaluated by imaging.
Patients with previous malignant tumors were not eligible to participate in the study unless they had achieved complete remission for at least 5 years prior to enrollment and did not require additional treatment or did not require additional treatment during the study.
Combined with serious internal medical diseases including but not limited to: uncontrolled diabetes, active peptic ulcer, active bleeding, etc.
Patients with insufficient communication, understanding and cooperation, or poor compliance, cannot be guaranteed to complete follow-up as required.
Muscle-invasive bladder cancer
Cohort
Prospective
Immunotherapy plus chemotherapy
DrugThe neoadjuvant therapy regimen for muscle-invasive bladder cancer is the GC regimen. This study does not alter the patients' neoadjuvant therapy regimen but adds toripalimab to the selected neoadjuvant treatment. After MDT discussion, eligible patients will receive GC combined with immunotherapy therapy.
pCR
The pathological complete response (pCR) rate evaluated by the pathological laboratory
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
